Dr. Daniel Friedman talks with Dr. Marc Gillinov of the Cleveland Clinic about a study that randomized patients undergoing mitral valve surgery to atrial fibrillation ablation and left atrial appendage ligation or no ablation. The study concluded that atrial fibrillation ablation improves rhythm control in patients undergoing cardiac surgery, though more patients undergoing ablation required permanent pacemaker placement. The study did not look at clinical outcomes beyond rhythm control.
Dr. Tiffany Randolph talks with Dr. Daniel Mark of the DCRI about an economic analysis of the PROMISE trial presented at ACC.15. PROMISE did not show a difference in outcomes between groups randomized to CT coronary angiography and usual care, and cost of care was equivalent between the groups, as the lower cost of CT coronary angiography was counterbalanced by a higher rate of invasive procedures in this group.
Dr. Matthew Sherwood, a fellow at the DCRI, talks about his poster, which used data from APPRAISE-2 to examine the effect of treatment with apixaban after acute coronary syndrome in patients with prior stroke. He concludes that treatment with apixaban after an acute coronary syndrome does not reduce the risk of cardiovascular outcomes in patients with a prior stroke, though it may have a beneficial effect in the subset of patients without prior stroke.
Dr. Emily Zeitler talks to Dr. Bernard Gersh of the Mayo Clinic about the LEGACY trial, a trial that compared physician-directed weight loss to usual care for the prevention of recurrent atrial fibrillation after ablation.
Dr. Lauren Cooper, a fellow at the DCRI, discusses her poster at ACC.15. Using pooled data from three trials in acute decompensated heart failure, she found no relationship between change in serum bicarbonate and outcomes.
Dr. Joe Sivak talks with Dr. Sreekanth Vemulapalli from the DCRI about the first year of outcomes data about MitraClip from the Transcatheter Valve Therapy registry. The analysis examined in-hospital and 30-day outcomes following the MitraClip procedure, as well as rates of procedural success and complications.
Dr. Amit Vora talks with Dr. Pamela Douglas of the DCRI about five-year outcomes from the high-risk cohort of the PARTNER trial, which compared transcutaneous aortic valve replacement (TAVR) with surgical aortic valve replacement (SAVR). Similar to data previously presented about three-year outcomes in PARTNER, five-year outcomes were equivalent between the groups for mortality, cardiovascular mortality, stroke, and hospitalization.
Dr. Jacob Kelly speaks with Dr. John Alexander of the DCRI about REGULATE PCI, a study comparing use of a new anticoagulant system, REG-1, to bivalrudin in patients undergoing percutaneous intervention. REG-1 is comprised of an anticoagulant, pegnivacogin, and an RNA aptamer, anivamersen, that is able to block to pegnivacogin’s activity if necessary. The trial was stopped early due to safety concerns regarding allergic reactions in patients receiving REG-1.
Dr. Sean Pokorney, a fellow at the DCRI, discusses his poster presented at ACC, The Myth of the Stable INR patient, in which he uses data from the ORBIT-AF registry to show that many patients on warfarin have INR values outside of the therapeutic range.
Dr. Adam Devore speaks to Dr. Marc Sabatine from Brigham and Women’s Hospital and the TIMI Study Group about PEGASUS TIMI 54, a trial comparing prolonged therapy with ticagrelor in patients with a prior myocardial infarction to the current standard of care.